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Introduction. Familial hemiplegic migraine (FHM) is a rare disorder characterized bymigraine attacks withmotor weakness during
the aura phase. Mutations in CACNA1A, ATP1A2, SCN1A, and PRRT2 genes have been described.Methods. To describe amutation
inATP1A2 gene in a FHMcasewith especially severe and prolonged symptomatology.Results. 22-year-oldwomanwas admitted due
to migraine-type headache and sudden onset of right-sided weakness and aphasia; she had similar episodes in her childhood. Her
mother was diagnosed with hemiplegic migraine without genetic confirmation. She presented with fever, decreased consciousness,
left gaze preference, mixed aphasia, right facial palsy, right hemiplegia, and left crural paresis. Computed tomography (CT) showed
no lesion andCTperfusion study evidenced oligohemia in left hemisphere. A normal brainmagnetic resonance (MR)was obtained.
Impaired consciousness and dysphasia began to improve three days after admission and mild dysphasia and right hemiparesis
lasted for 10 days. No recurrences were reported during a follow-up of two years. We identified a variant in heterozygous state
in ATP1A2 gene (p.Thr364Met), pathogenic according to different prediction algorithms (SIFT, PolyPhen2, MutationTaster, and
Condel). Conclusion. Prolonged and severe attacks with diffuse hypoperfusion in a FHM seemed to be specially related to ATP1A2
mutations, and p.T364M should be considered.
1. Introduction
Familial hemiplegic migraine (FHM) is an uncommon type
of migraine with aura including motor weakness with at
least one first- or second-degree relative affected [1]. FHM is
considered a monogenic disorder with autosomal dominant
inheritance pattern. Though there may be other loci to be
identified, FHM is subdivided into three types: FHM1 with
mutations in CACNA1A gene on chromosome 19, FHM2 in
ATP1A2 gene on chromosome 1, and FHM3 in which muta-
tions in SCN1A gene on chromosome 2 have been identified
[1]. These genes are implicated not only in ion channel but
also in other molecules as synaptosomal associated protein.
Moreover, there are typical cases that do not have a mutation
in one of the main genes described, suggesting that other
genes are still to be identified [2].
The clinical spectrum of this disorder varies from mod-
erate headache accompanied by motor weakness to coma,
with description of cases associated with permanent ataxia,
epileptic seizures, mental retardation, and chronic progres-
sive cerebellar atrophy [2].
We describe a mutation inATP1A2 gene in a case of FHM
with especially severe attacks.
2. Case Report
A 22-year-old Caucasian woman was admitted due to a clini-
cal picture of right-sided weakness and aphasia accompanied
by a migraine-type headache (throbbing pain on the left side,
with nausea and photophobia) initiated when she woke up.
She had previously suffered similar clinical episodes 7 years
before and during her childhood. Her mother presented with
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Figure 1: Perfusion computed tomography. TC revealed increased mean transit time (a) and diminished cerebral blood flow (b) with
preserved cerebral volume (c). These changes were observed throughout the entire left cerebral hemisphere not confined to a particular
vascular territory including the territory of anterior, middle, and posterior cerebral arteries (PCA).
multiple episodes of migraine with motor weakness. Our
patient was adopted during early childhood and did not have
a relationshipwith her family; so, amore accurate description
on her mother’s clinical picture was not available. She has no
brothers or sisters.
In the anamnesis of possible triggers, she reported that,
ten days before admission, she had suffered a mild head
trauma during a traffic collision (she did not call for medical
care for this reason). At admission, clinical exam showed a left
gaze preference, predominantly nonfluent aphasia, and right
facial palsy with right hemiplegia.
Urgent unenhanced CT was normal, but perfusion CT
revealed increased mean transit time (MTT) and dimin-
ished cerebral blood flow (CBF) throughout the entire left
cerebral hemisphere not confined to a particular vascular
territory including the territory of anterior (ACA), middle
(MCA), and posterior cerebral arteries (PCA) (Figure 1).
Cerebral blood volume (CBV) was normal. Findings were
consistent with hypoperfusion throughout all the left cerebral
hemisphere. Cerebrovascular study was completed with an
angiography TC and carotid ultrasound with no alterations.
Transcranial Duplex revealed a generalized acceleration
in both middle cerebral arteries with absence of arterial
occlusion. A diffusion-weighted brain magnetic resonance
imaging (DWB-MRI) was performed 3 days after clinical
onset and it showed no restricted diffusion on the region
of perfusion abnormality with normal signal intensity of the
brain parenchyma.
On the second day, aphasia worsened, and somnolence
and body temperature of 38∘ appeared. A lumbar punc-
ture was performed without pleocytosis nor hyperproteinor-
rachia. Cerebrospinal fluid (CSF)microbiological studies and
serum extensive biochemical, hematological, or immunolog-
ical determinations were carried out with normal results. An
electroencephalogram (EEG) recording showed diffuse delta
activity.
The patient was empirically treated with acetylsalicylic
acid and acyclovir during the first days. The clinical picture
evolved favorably but in a slow way; fever and diminished
level of consciousness disappeared on day 4, and motor
deficit and dysphasia resolved, respectively, 6 and 8 days after
onset. No recurrence of neurological symptomswas observed
during a follow-up of 2 years.
As usual in our protocols for FHM studies, we carried
out exome sequencing and subsequently analyzed the coding
sequences of SCN1A, CACNA1A, ATP1A2, NOTCH3, and
PRRT2 genes in order to identify potential pathogenic muta-
tions. DNA was extracted from peripheral blood according
to standard protocols. DNA quality was determined by
continuous reading of optical density with the Nanodrop
equipment. Its integrity was checked by electrophoresis and
SYBR Green II staining. After checking the quality, we
proceeded to the capture and massive sequencing of human
gene exons by using the SureSelect Human All Exon Kit 51
Mb (Agilent) assay and Hiseq2000 (Illumina) sequencer
with a 30x mean coverage depth. The bioinformatic analysis
allowed us to identify single nucleotide variants and small
insertions and deletions relative to the reference genome [25].
Once obtained, the exonic sequences were aligned against the
human genome reference, and we proceeded to the selective
detection of all possible variants in candidate genes. Variants
reported with frequencies over 1% in dbSNP, 1000 Genomes,
and Exome Variant Server were excluded and the results
were analyzed assuming a dominant model of inheritance
according to the model expected for the disease and the
indicated genes.
We identified a heterozygous variantwithinATP1A2 gene.
This variant has not been reported in more than 6500 control
individuals [26]. Sequence analysis revealed C>T transition
(missense mutation) in position 160098515 of chromosome
1. This variation in ATP1A2 gene produces Thr to Met
amino acid substitution at position 364 of the coded protein
(p.T364M).
The substituted amino acid is strongly conserved, since it
is present in homologous proteins in all recorded mammals,
reptiles, and fishes. Several in silico tests strongly suggest
that Thr to Met substitution should strongly affect the
ATP1A2 function: PolyPhen shows a damaging score of 1.000
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Table 1: Mutations described in ATP1A2 gene related to FHM.
Mutation Phenotypic characteristics
D718N [1] Long-lasting hemiplegic migraine, seizures, and mental retardation
P979L [1] Recurrent coma, seizures, mental retardation, and interictal mild cerebellar signs
R689Q [2] Benign familial infantile convulsions
K7940 [2] Spectrum between alternating hemiplegia of childhood (AHC) and FHM
A1033G, T345A [3] Coma
E700K [2] FHM
R593W and V628M [4] FHM
M731T and T376M [5] Pure FHM
A606T, N717K, R1002Q [6] Severe hemiplegia
T415M [7] Dysphasia and drowsiness and attacks triggered by mild head injury
V362E [8] Mood alterations, classified as a borderline personality
P796S [8] Mild mental impairment, in addition to hemiplegic migraine
D999H [8, 9] Seizures
G900R [8] Coma, high fever, and status epilepticus
G301R [10, 11] FHM with interictal cerebellar symptoms
R548C [12] Epilepsy
G855R [13] Febrile seizures
G902L [14] Fever, coma, and cortical edema in MR
V338A, Q927P [11] Coma
G715R [15] Aphasia, coma, and brain edema
R548H [16] Hemiplegic migraine associated with basilar migraine
M731T [17] Psychotic aura symptoms
p.T364M [18] Prolonged hemiplegia, aphasia, somnolence, and fever in a child
R1007W [19] Drowsiness with myoclonic seizures
S220L, R908Q [20] Coma and aphasia
M731T [21] Psychotic aura
R908Q [22] FHM with prolonged aura
p.A348p [23] Large family and severe and long-lasting attacks with coma and fever
c.G571A [24] Neurosensorial hearing loss
and reports that Thr is always conserved in this position
when compared with the homologous gene of 43 species;
MutationTaster software test gives a probability of disease
causing over 0.9999 and reports that this mutation has not
been reported in 1000G or in ExAC databases; and, finally,
SITF test gives a PROVEAN score of −5.166 (variants with
scores under −2.5 are considered deleterious).
No further potential pathogenic mutations were found
within ATP1A2 or in the remaining candidate genes studied.
The variant was validated by Sanger sequencing.
3. Discussion
FHM is a clinically heterogeneous disorder, with attacks vary-
ing frommild hemiparesis to severe long-lasting hemiplegia.
Rare disturbances of consciousness (sometimes including
coma), confusion, fever, and cerebrospinal fluid pleocytosis
may occur [2].
There are more than 60 different missense mutations
in ATP1A2 gene. Other heterozygous mutations in ATP1A2
gene have been reported in FHM patients [3–6, 9, 18].
We present a table with the mutations described in the
literature from 2003 to 2016 and their main phenotypic
characteristics (Table 1). Some of themutations produce long-
lasting attacks of hemiplegic migraine, but they are related to
other neurological pathologies such as seizures and mental
retardation [1], coma, and fever [23].The case we present had
no other neurological diseases apart from FHM.
To understand the relationship of the ATP1A2 gene with
seizures, migraine, and coma, it is important to understand
the pathophysiology of the mutations in ATP1A2 gene. This
gene is on chromosome 1q23 and encodes 𝛼-2 subunit of
Na+/K+ ATPase plasmamembrane enzyme, which consumes
ATP to actively transport Na+ out of the cell and K+ into
the cell [9]. Na+/K+ ATPase protein is composed of three
heteromeric subunits (𝛼, 𝛽, and 𝛾), and 𝛼 is the catalytic
one, which is composed of two subunits. The 𝛼-2 subunit
is expressed in central nervous tissue, particularly astrocytes
and pyramidal cells in the hippocampus. This 𝛼-2 subunit
is composed of N-terminal region containing 4 membrane-
spanning domains (M1–M4) and C-terminal region con-
taining 6 membrane-spanning domains (M5–M10), which
are linked by a large intracellular loop. This large M4-M5
loop contains critical functional sites and undergoes major
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conformational changes during the enzymatic cycle. Most of
theATP1A2 genemutations causing FHM2 are located within
this loop [9]. In fact, the described mutation affects the M4-
M5 loop. In silico software predicts severe conformational
changes within this domain on the mutated protein. More-
over, Thr amino acid is highly conserved underlining its key
role in this location of ATP1A2 protein. This variation in
ATP1A2 gene produces Thr to Met amino acid substitution
at position 364 of the coded protein (p.T364M), leading to
the dysfunction of the gene.
As Na+/K+ ATPase exchanges intracellular Na+ for extra-
cellular K+, loss of Na+/K+ ATPase function results in raised
extracellular K+, which facilitates cortical spreading depres-
sion, the mechanism postulated to cause migraine aura. This
ATPase dysfunction also results in raised intracellular Na+,
which will increase intracellular Ca2+ levels as a result of
a decrease in Na+/Ca2+ exchange. This raised intracellular
Ca2+ also facilitates the cortical spreading depression [9] with
the consequent hypoperfusion as we have shown in Figure 1.
These biochemical alterations are capable of producing pro-
longed functional impairment but without causing lesion on
neuroimaging (MRI).
The mutation present in our patient was previously
described in an eight-year-old female who presented with
prolonged attacks including hemiplegia, aphasia, lethargy,
and fever [18]. As in our case, cerebrospinal fluid was
unremarkable, and electroencephalogram showed diffuse
slowing. Hypoperfusion was not shown in perfusion CT as
in our patient.
4. Conclusion
In conclusion, prolonged and severe attacks with diffuse
hypoperfusion in a FHM seemed to be specially related
to ATP1A2 mutations, and p.T364M mutation should be
considered.
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